In this study, we found that mGPDH was decreased in melanoma tissue, especially metastatic melanoma, which predicted a poor clinical outcome, and that the loss of mGPDH promoted metastasis by up‐regulating the NRF2 signalling pathway. The gene discussed is GPD2; the disease is metastatic melanoma.